Clin2
NCT07782164Possibly a fitRecruiting

Irreversible electroporation for recurrent pelvic tumors

Colorectal CarcinomaRenal CancerBladder CancerCervical CancerProstate CancerOvarian CancerLung Cancer (Including Metastatic Cancer)Anal Cancer

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.

This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
27 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have a pelvic tumor that has recurred (come back) after previous treatment.
  • The tumor can be measured on a recent imaging scan (CT, MRI, or PET) taken within the last 6 weeks.
  • You are not eligible for or have not responded to standard local treatments like surgery or stereotactic body radiation therapy (SBRT).
  • A recent biopsy of the tumor must not show that it is benign (non-cancerous).
  • You must have sufficient health data recorded before the procedure.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06886321Not yet recruiting
Testing a new non-surgical prostate cancer treatment

This trial tests a new, non-surgical treatment called irreversible electroporation (IRE) for men with early-stage prostate cancer that hasn't spread. It uses short electrical pulses to destroy cancer cells while sparing healthy tissue nearby.

Hong Kong
NCT06451445Recruiting
Focal IRE treatment for intermediate-risk prostate cancer

This trial tests a new focal treatment called IRE (irreversible electroporation) that uses electrical pulses to destroy prostate cancer cells while sparing healthy tissue. It is for men with intermediate-risk prostate cancer that has not spread outside the prostate gland.

Toronto, Ontario
NCT06185556Recruiting· Phase 2/Phase 3
New treatments for liver tumors near blood vessels or bile ducts

This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.

Amsterdam, North Holland
NCT07191548Not yet recruiting
IRE treatment for colorectal cancer that spread to the liver

This trial tests a treatment called IRE (a type of non-thermal ablation) for colorectal cancer that has spread to the liver. It aims to see if IRE can safely and effectively treat these liver tumors, offering a possible option for patients who may not be candidates for surgery or thermal ablation.

Manchester
NCT07192731Not yet recruiting
IRE for liver cancer patients

This trial tests a treatment called IRE (irreversible electroporation) for people with liver cancer that hasn't spread. It uses electrical pulses to destroy tumors without heat or cold, and you may qualify if you have up to 3 small tumors and are otherwise healthy enough for the procedure.

Manchester
NCT06677762Not yet recruiting
IRE ablation with immunotherapy for advanced pancreatic cancer

This study looks back at people with advanced pancreatic cancer who received a treatment called IRE (a special type of ablation) along with immunotherapy. The goal is to see how well this combination works and how safe it is for patients whose cancer cannot be removed with surgery.

Hear when a new Colorectal Neoplasms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.